We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Intercept Pharmaceuticals Inc
17 own
17 watching
Current Price
$10.45
$-0.03
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
510.67M
52-Week High
21.86000
52-Week Low
8.82000
Average Volume
0.74M
Dividend Yield
--
P/E Ratio
--
Market Capitalization510.67M52-Week High21.8600052-Week Low8.82000Average Volume0.74MDividend Yield--P/E Ratio--What does the Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More
How much money does Intercept Pharmaceuticals Inc make?
News & Events about Intercept Pharmaceuticals Inc.
Globe Newswire
3 months ago
Planned interim analysis from the first of two Phase 2 studies shows combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in 58% of patients at 12 weeks ALP normalized in 75% of patients in the OCA 5-10 mg + bezafibrate 400 ...
PR Newswire
3 months ago
Thinking about buying stock in SoundHound AI, Virios Therapeutics, Locafy, Intercept Pharmaceuticals, or D-Wave Quantum? Thinking about buying stock in SoundHound AI, Virios Therapeutics, Locafy, Intercept Pharmaceuticals, or D-Wave Quantum? PR Newswire NEW YORK, June 23, 2023 NEW YORK, June 23...
Globe Newswire
3 months ago
Measures reinforce Companys ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by approximately one third Company anticipates achieving profitability in 2024R&D investment prioritized on ...
Globe Newswire
3 months ago
NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (Intercept or the Company) (NASDAQ:ICPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
Zolmax
5 months ago
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT Get Rating) B. Riley raised their FY2023 earnings estimates for shares of Intercept Pharmaceuticals in a report issued on Monday, April 24th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $0.19 per share for the ...
Frequently Asked Questions
Frequently Asked Questions
What is Intercept Pharmaceuticals Inc share price today?
Can Indians buy Intercept Pharmaceuticals Inc shares?
How can I buy Intercept Pharmaceuticals Inc shares from India?
Can Fractional shares of Intercept Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Intercept Pharmaceuticals Inc stocks?
What is today’s traded volume of Intercept Pharmaceuticals Inc?
What is today’s market capitalisation of Intercept Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Intercept Pharmaceuticals Inc?
What percentage is Intercept Pharmaceuticals Inc down from its 52-Week High?
What percentage is Intercept Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$10.45
$-0.03
(-0.29%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.